Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Article in ESMO Open (May 2024)
The most recent citing publications are shown below. View all 219 publications that cite this research output on Dimensions.
Article in ESMO Open (May 2024)
Article in The Breast (April 2024)
Article in Clinical and Translational Oncology (March 2024)